C0916853_interactsWith_C4288736 | Knowledge4COVID-19

Property	Value
?:effect	<https://research.tib.eu/covid-19/entity/C0001688>
?:hasPrimarySource	<https://research.tib.eu/covid-19/SourceName/UMLS>
?:impact	increase
?:interaction	The risk or severity of adverse effects can be increased when Pexelizumab is combined with Mirvetuximab Soravtansine.
?:objectDrug	<https://research.tib.eu/covid-19/entity/C4288736>
?:object_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB12489>
?:precipitantDrug	<https://research.tib.eu/covid-19/entity/C0916853>
?:precipitant_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB04949>
is ?:subClassOf of	<https://research.tib.eu/covid-19/entity/C0916853_hasPharmacodynamic_C4288736>
?:type	<https://research.tib.eu/covid-19/vocab/DrugDrugInteraction>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/C0916853_interactsWith_C4288736>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/C0916853_interactsWith_C4288736>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all